
CLAIMS

What is claimed is:

1. A compound of Formula (II):



(II)

or stereoisomers, tautomer, solvates or salts thereof, wherein:

X is N or CR_3;

one of Q_1 and Q_2 is A and the other of Q_1 and Q_2 is R_5;

G is phenyl substituted with $-S(O)_2CH_3$, $-S(O)_2$(phenyl), $-S(O)_2NR_xR_x$, or $-S(O)(NH)NR_xR_x$;

A is cyclohexyl, piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl, or azabicyclo[3.2.1]octanyl, each substituted with $-L-R_4$ and zero to 1 R_{4b};


L is a bond, $-CR_xR_x-$ or $-C(O)(CR_xR_x)_{0-2}-$;

R_3 is hydrogen, F, Cl, C_{1-3} alkyl, C_{1-2} fluoroalkyl, or C_{3-4} cycloalkyl;

R_4 is:

(i) $-N(CH_3)_2$;

(ii) pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, pyridinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with zero to 2 R_{4a}; or

(iii) 

;

each R_{4a} is independently C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-(CH_2)_{0-2}O(C_{1-2}$ alkyl), C_{3-6} cycloalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)(C_{3-6}$ cycloalkyl), $-C(O)$(phenyl), $-C(O)CH_2(C_{3-6}$ cycloalkyl), $-C(O)CH_2$(phenyl), $-C(O)O(C_{1-4}$ alkyl), oxetanyl, tetrahydrofuran, or tetrahydropyranyl;

R_{4b} is F, Cl, or $-CH_3$;

each R_{4c} is independently C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)$(phenyl), $-C(O)CH_2$(phenyl), $-C(O)OCH_2CH_3$, or C_{3-6} cycloalkyl;

each R_5 is independently hydrogen, F, Cl, C_{1-3} alkyl, C_{1-2} fluoroalkyl, or C_{3-4} cycloalkyl;

each R_x is independently hydrogen or $-CH_3$;

m is zero, 1, or 2;

n is zero, 1, or 2; and

q is 1 or 2.

2. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein X is CR_3.

3. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein X is N.

4. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein:

G is phenyl substituted with $-S(O)_2CH_3$;

A is cyclohexyl, piperidinyl, phenyl, or 6-azabicyclo[3.2.1]octanyl, each substituted with $-L-R_4$;

L is a bond;


R_3 is hydrogen;

R_4 is piperidinyl, piperazinyl, azepanyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with R_{4a};

R_{4a} is $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-CH_2CH_2OCH_3$, $-C(O)CH(CH_3)_2$, $-C(O)$(cyclopropyl), $-CH_2$(cyclopropyl), $-CH_2$(cyclobutyl), cyclopropyl, cyclobutyl, oxetanyl, or tetrahydropyranyl; and

each R_5 is hydrogen, F, or $-CH_3$.

5. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein:

G is .

6. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein said compound is:

6-(1'-cyclopropyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (7);

6-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (8);

6-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (9);

6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (62-63);

7-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-5-methyl-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (66);

8-fluoro-6-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (67);

8-fluoro-6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (68-69);

7-fluoro-6-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (70);

8-fluoro-6-(1-(1-isopropylazepan-4-yl)piperidin-4-yl)-2-(4-(methylsulfonyl) phenyl)imidazo[1,2-a]pyridine (71-72);

5-fluoro-6-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (73);

8-fluoro-7-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (74);

6-(1-(8-cyclobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (83-84);

6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (85-86);

6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-

methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (87-88);

6-(1-(8-(cyclobutylmethyl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (89-90);

6-(1'-cyclobutyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (91);

6-(1'-(cyclopropylmethyl)-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl) phenyl)imidazo[1,2-a]pyridine (92);

6-(1'-(cyclobutylmethyl)-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl) phenyl)imidazo[1,2-a]pyridine (93);

6-(4-(4-isobutylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (99);

6-(4-(4-(cyclopropylmethyl)piperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (100);

6-(4-(4-(cyclobutylmethyl)piperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl) phenyl)imidazo[1,2-a]pyridine (101);

6-(4-(4-cyclobutylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (102);

8-methyl-2-(4-(methylsulfonyl)phenyl)-6-(4-(4-(oxetan-3-yl)piperazin-1-yl) phenyl)imidazo[1,2-a]pyridine (103);

8-methyl-2-(4-(methylsulfonyl)phenyl)-6-(4-(4-(tetrahydro-2H-pyran-4-yl) piperazin-1-yl)phenyl)imidazo[1,2-a]pyridine (104);

6-(4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl) phenyl)imidazo[1,2-a]pyridine (105);

7-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-5-methyl-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (106);

8-fluoro-6-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (107);

6-(1'-cyclopropyl-[1,4'-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (108);

6-(1'-(cyclopropylmethyl)-[1,4'-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl) phenyl)imidazo[1,2-a]pyridine (109);

6-(1'-cyclobutyl-[1,4'-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)

imidazo[1,2-a]pyridine (110);

8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1'-(oxetan-3-yl)-[1,4'-bipiperidin]-4-yl) imidazo[1,2-a]pyridine (111);

8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1'-(tetrahydro-2H-pyran-4-yl)-[1,4'-bipiperidin]-4-yl)imidazo[1,2-a]pyridine (112);

8-fluoro-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (113-114);

6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (115-116);

6-(1-(8-cyclobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (117);

6-(1-(8-cyclobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (118);

8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1-(8-(oxetan-3-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)imidazo[1,2-a]pyridine (119-120);

8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1-(8-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)imidazo[1,2-a]pyridine (121-122);

7-fluoro-6-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (123);

6-(1'-cyclopropyl-[1,4'-bipiperidin]-4-yl)-7-fluoro-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (124);

8-fluoro-6-(1-(1-isobutylazepan-4-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (125-126);

6-(1-(1-(cyclopropylmethyl)azepan-4-yl)piperidin-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (127-128);

8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1-(1-(tetrahydro-2H-pyran-4-yl)azepan-4-yl)piperidin-4-yl)imidazo[1,2-a]pyridine (129-130);

5-fluoro-6-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (131);

8-fluoro-7-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1,2-a]pyridine (132);

8-fluoro-2-(4-(methylsulfonyl)phenyl)-7-(1'-(tetrahydro-2H-pyran-4-yl)-[1,4'-

bipiperidin]-4-yl)imidazo[1,2-a]pyridine (133);

6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (147);

6-(4-(8-isopropyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (153);

6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (159);

6-(8-(1-isopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (160);


6-(1'-cyclopropyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (161);

6-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (162);

6-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (163); or

6-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (167).

8. A compound of Formula (III):



(III)

or stereoisomers, tautomer, solvates or salts thereof, wherein:

X is N or CR_3;

one of Q_1 and Q_2 is A and the other of Q_1 and Q_2 is R_5;

G is phenyl substituted with 1 to 3 substituents independently selected from F, Cl, Br, $C_{1–2}$ alkoxy, C_{1-2} fluoroalkoxy, C_{3-4} cycloalkyl, $-C(O)NR_yR_y$, $-S(O)_2CH_3$, $-S(O)_2$(phenyl), $-S(O)_2NR_xR_x$, and $-S(O)(NH)NR_xR_x$;

A is cyclohexyl, piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl, or azabicyclo[3.2.1]octanyl, each substituted with $-L-R_4$ and zero to 1 R_{4b};


L is a bond, $-CR_xR_x-$ or $-C(O)(CR_xR_x)_{0-2}-$;

R_3 is hydrogen, F, Cl, C_{1-3} alkyl, C_{1-2} fluoroalkyl, or C_{3-4} cycloalkyl;

R_4 is:

(i) $-N(CH_3)_2$;

(ii) pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, pyridinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with zero to 2 R_{4a}; or

(iii) 

;

each R_{4a} is independently C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-(CH_2)_{0-2}O(C_{1-2}$ alkyl), C_{3-6} cycloalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)(C_{3-6}$ cycloalkyl), $-C(O)$(phenyl), $-C(O)CH_2(C_{3-6}$ cycloalkyl), $-C(O)CH_2$(phenyl), $-C(O)O(C_{1-4}$ alkyl), oxetanyl, tetrahydrofuran, or tetrahydropyranyl;

R_{4b} is F, Cl, or $-CH_3$;

each R_{4c} is independently C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)$(phenyl), $-C(O)CH_2$(phenyl), $-C(O)OCH_2CH_3$, or C_{3-6} cycloalkyl;

each R_5 is independently hydrogen, F, Cl, C_{1-3} alkyl, C_{1-2} fluoroalkyl, or C_{3-4} cycloalkyl;

each R_x is independently hydrogen or $-CH_3$;

each R_y is independently hydrogen or C_{1-6} alkyl;

m is zero, 1, or 2;

n is zero, 1, or 2; and

q is 1 or 2.

9. The compound according to claim 8 or stereoisomers, tautomer, solvates or salts thereof, wherein X is CR_3.

10. The compound according to claim 8 or stereoisomers, tautomer, solvates or salts thereof, wherein X is N.

11. The compound according to claim 8 or stereoisomers, tautomer, solvates or salts thereof, wherein:

G is phenyl substituted with 1 to 2 substituents independently selected from F, $-OCH_3$, and $-S(O)_2CH_3$;

A is cyclohexyl, piperidinyl, phenyl, or 6-azabicyclo[3.2.1]octanyl, each substituted with $-L-R_4$;

L is a bond;


R_3 is hydrogen;

R_4 is piperidinyl, piperazinyl, azepanyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with R_{4a};

R_{4a} is $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-CH_2CH_2OCH_3$, $-C(O)CH(CH_3)_2$, $-C(O)$(cyclopropyl), $-CH_2$(cyclopropyl), $-CH_2$(cyclobutyl), cyclopropyl, cyclobutyl, oxetanyl, or tetrahydropyranyl; and

each R_5 is hydrogen, F, or $-CH_3$.

12. The compound according to claim 8 or stereoisomers, tautomer, solvates or salts thereof, wherein:

G is .

13. The compound according to claim 8 or stereoisomers, tautomer, solvates or salts thereof, wherein said compound is:

2-(3,4-dimethoxyphenyl)-6-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (31-33);

2-(3,4-dimethoxyphenyl)-6-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (34-36);

6-(1'-cyclopropyl-[1,4'-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (37-38);

1-(4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)-[1,4'-bipiperidin]-1'-yl)-2-methylpropan-1-one (39-41);

cyclopropyl(4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a] pyridin-6-yl)-[1,4'-bipiperidin]-1'-yl)methanone (42-44);

-(3,4-dimethoxyphenyl)-6-(1-(2-isopropyl-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (45-47);

6-(1-(2-cyclobutyl-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (48-50);

6-(1-(2-(cyclopropylmethyl)-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (51);

2-(3,4-dimethoxyphenyl)-6-(1-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (52-54);

6-(1'-(cyclopropylmethyl)-[1,4'-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (55-57);

2-(3,4-dimethoxyphenyl)-7-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (58);

2-(3,4-dimethoxyphenyl)-7-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (59);

(6R)-2-(3,4-dimethoxyphenyl)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (75-76);

(6S)-2-(3,4-dimethoxyphenyl)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (77-78);

(6R)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (79-80);

(6S)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (81-82);

(6R)-2-(3,4-dimethoxyphenyl)-6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (134-135);

(6S)-2-(3,4-dimethoxyphenyl)-6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (136-137);

(6R)-6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (138-139);

(6S)-6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (140-141);

2-(3,4-dimethoxyphenyl)-6-(4-(4-isopropylpiperazin-1-yl)cyclohexyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine (143);

2-(3,4-dimethoxyphenyl)-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine (144);

6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine (145);


2-(3,4-dimethoxyphenyl)-6-(8-(1-isopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine (148);

6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine (150);

2-(3,4-dimethoxyphenyl)-6-(4-(8-isopropyl-3,8-diazabicyclo[3.2.1]octan-3-yl) phenyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine (152); or

6-(4-(8-isopropyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine (154).

14. A compound of Formula (IIb):



(IIb)

or stereoisomers, tautomer, solvates or salts thereof, wherein:

one of Q_1 and Q_2 is A and the other of Q_1 and Q_2 is R_5;

G is phenyl substituted with 1 to 3 substituents independently selected from F, Cl, Br, $C_{1–2}$ alkoxy, C_{1-2} fluoroalkoxy, C_{3-4} cycloalkyl, or $–C(O)NR_yR_y$;

A is cyclohexyl, piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl, or azabicyclo[3.2.1]octanyl, each substituted with $–L–R_4$ and zero to 1 R_{4b};


L is a bond, $–CR_xR_x–$ or $–C(O)(CR_xR_x)_{0-2}–$;

R_3 is hydrogen, F, Cl, C_{1-3} alkyl, C_{1-2} fluoroalkyl, or C_{3-4} cycloalkyl;

R_4 is:

(i) $-N(CH_3)_2$;

(ii) pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, pyridinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with zero to 2 R_{4a}; or

(iii)  ;

each R_{4a} is independently C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-(CH_2)_{0-2}O(C_{1-2}$ alkyl), C_{3-6} cycloalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)(C_{3-6}$ cycloalkyl), $-C(O)$(phenyl), $-C(O)CH_2(C_{3-6}$ cycloalkyl), $-C(O)CH_2$(phenyl), $-C(O)O(C_{1-4}$ alkyl), oxetanyl, tetrahydrofuran, or tetrahydropyranyl;

R_{4b} is F, Cl, or $-CH_3$;

each R_{4c} is independently C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)$(phenyl), $-C(O)CH_2$(phenyl), $-C(O)OCH_2CH_3$, or C_{3-6} cycloalkyl;

each R_5 is independently hydrogen, F, Cl, C_{1-3} alkyl, C_{1-2} fluoroalkyl, or C_{3-4} cycloalkyl;

each R_x is independently hydrogen or $-CH_3$;

m is zero, 1, or 2;

n is zero, 1, or 2; and

q is 1 or 2.

15. The compound according to claim 14 or stereoisomers, tautomer, solvates or salts thereof, wherein:

G is phenyl substituted with 1 to 2 substituents independently selected from F or $-OCH_3$;

A is cyclohexyl, piperidinyl, phenyl, or 6-azabicyclo[3.2.1]octanyl, each substituted with $-L-R_4$;

L is a bond;



R_3 is hydrogen;

R_4 is piperidinyl, piperazinyl, azepanyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with R_{4a};

R_{4a} is $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-CH_2CH_2OCH_3$, $-C(O)CH(CH_3)_2$, $-C(O)$(cyclopropyl), $-CH_2$(cyclopropyl), $-CH_2$(cyclobutyl), cyclopropyl, cyclobutyl, oxetanyl, or tetrahydropyranyl; and

each R_5 is hydrogen, F, or $-CH_3$.

16. The compound according to claim 14 or stereoisomers, tautomer, solvates or salts thereof, wherein:

G is  or .

17. The compound according to claim 14 or stereoisomers, tautomer, solvates or salts thereof, wherein said compound is:

2-(3,4-dimethoxyphenyl)-7-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a] pyridine (60);

2-(3,4-dimethoxyphenyl)-7-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a] pyridine (61);

2-(3,4-dimethoxyphenyl)-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (142);

6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine (146);

2-(3,4-dimethoxyphenyl)-6-(8-(1-isopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-[1,2,4]triazolo[1,5-a]pyridine (149);

2-(3,4-dimethoxyphenyl)-6-(4-(8-isopropyl-3,8-diazabicyclo[3.2.1]octan-3-yl) phenyl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (151);

6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (155);

2-(3,4-dimethoxyphenyl)-6-(8-(1-isopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (156);

6-(1'-cyclopropyl-[1,4'-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (157);

2-(3,4-dimethoxyphenyl)-6-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine (158);

6-(1'-cyclopropyl-[1,4'-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine (164);

2-(3,4-dimethoxyphenyl)-6-(1'-isopropyl-[1,4'-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a] pyridine (165); or

2-(3,4-dimethoxyphenyl)-6-(4-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl) phenyl)-[1,2,4]triazolo[1,5-a]pyridine (166).

18. A pharmaceutical composition comprising one or more compounds according to any one of claim 1 to 17, stereoisomers, tautomer, solvates or pharmaceutically-acceptable salts thereof; and a pharmaceutically acceptable carrier.

19. A compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof, or a composition according to claim 18 for use in therapy.

20. A compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof, or a composition according to claim 18 for use in therapy in treating liver fibrosis, renal fibrosis, biliary fibrosis, pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).